Literature DB >> 17669010

Improving vaccines by incorporating immunological coadjuvants.

Cara K Fraser1, Kerrilyn R Diener, Michael P Brown, John D Hayball.   

Abstract

While vaccination continues to be the most successful interventionist health policy to date, infectious disease remains a significant cause of death worldwide. A primary reason that vaccination is not able to generate effective immunity is a lack of appropriate adjuvants capable of initiating the desired immune response. Adjuvant combinations can potentially overcome this problem; however, the possible permutations to consider, which include the route and kinetics of vaccination, as well as combinations of adjuvants, are practically limitless. This review aims to summarize the current understanding of adjuvants and related immunological processes and how this knowledge can and has been applied to the strategic selection of adjuvant combinations as components of vaccines against human infectious disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669010     DOI: 10.1586/14760584.6.4.559

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  26 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 2.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Evaluation of three experimental bovine viral diarrhea virus killed vaccines adjuvanted with combinations of Quil A cholesterol and dimethyldioctadecylammonium (DDA) bromide.

Authors:  Julia F Ridpath; Paul Dominowski; Ramasany Mannan; Robert Yancey; James A Jackson; Lucas Taylor; Sangita Mediratta; Robert Eversole; Charles D Mackenzie; John D Neill
Journal:  Vet Res Commun       Date:  2010-09-28       Impact factor: 2.459

4.  Dear SIRS, the concept of "alarmins" makes a lot of sense!

Authors:  Jérôme Pugin
Journal:  Intensive Care Med       Date:  2007-10-17       Impact factor: 17.440

5.  MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Authors:  Barbara C Baudner; Vanessa Ronconi; Daniele Casini; Marco Tortoli; Jina Kazzaz; Manmohan Singh; Lynn D Hawkins; Andreas Wack; Derek T O'Hagan
Journal:  Pharm Res       Date:  2009-03-03       Impact factor: 4.200

Review 6.  Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines.

Authors:  Shishir Kumar Gupta; Preety Bajwa; Rajib Deb; Madhan Mohan Chellappa; Sohini Dey
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

7.  No human protein is exempt from bacterial motifs, not even one.

Authors:  Brett Trost; Guglielmo Lucchese; Angela Stufano; Mik Bickis; Anthony Kusalik; Darja Kanduc
Journal:  Self Nonself       Date:  2010-10

8.  Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Paul E Makidon; Katarzyna W Janczak; Luz P Blanco; Benjamin Swanson; Douglas M Smith; Tiffany Pham; Zsuzsanna Szabo; Jolanta F Kukowska-Latallo; James R Baker
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

Review 9.  Peptide vaccines for hematological malignancies: a missed promise?

Authors:  Monica Bocchia; Marzia Defina; Lara Aprile; Anna Sicuranza
Journal:  Int J Hematol       Date:  2014-01-08       Impact factor: 2.490

10.  Hepatitis B virus and Homo sapiens proteome-wide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins.

Authors:  Rosalia Ricco; Darja Kanduc
Journal:  Biologics       Date:  2010-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.